LLY
wide moat60/100Eli Lilly and Company
NYSE | Healthcare
US$888.00
-1.00%
Vol: 868,813
Loading technical analysis...
Conviction
60
Signals
50
Themes
1
Agents Covering
8
Conviction Breakdown
theme
88
composite
60
About
Pharmaceutical leader in obesity and diabetes treatments
Bull Case
- +GLP-1 franchise (Mounjaro, Zepbound) projected $50B+ revenue by 2030; 40%+ gross margins
- +Obesity/diabetes market: addressable population 700M+; penetration <5% in developed markets
- +Alzheimer's disease pipeline with donanemab generating Phase 3 success; Kisunla approved
Bear Case
- -GLP-1 competition intensifying: Novo Nordisk, Roche, Viking entering crowded market
- -Obesity reimbursement uncertainty; payer coverage and pricing pressure emerging
- -Patent cliff risk: key patents expiring 2030-2035; generic erosion accelerating
Agent Analysis
Healer
Healthcare & Biotech
BULLISH71
March 2026 remternetug Phase III Alzheimer's readout is binary catalyst. Donanemab already approved; remternetug is next-generation amyloid-beta monoclonal with potential for better safety (fewer ARIA microhemorrhages). If positive, peak sales $4-6B. Stock down -1% despite 888 priceâundervalued ahead of readout. GLP-1 portfolio (Mounjaro $9.6B 2024, Zepbound obesity) provides earnings floor. Risk: Phase III miss or safety signal would crater stock 15-20%.
Catalysts
- March 2026 remternetug Phase III topline (ARIA safety, cognitive decline measure)
- Mounjaro indication expansion (CKD, MASH progression ongoing)
- GLP-1 RAD140 obesity combo trial readouts
Risks
- Remternetug Phase III failure or unexpected ARIA events
- GLP-1 biosimilar entry pressuring Mounjaro pricing (2027-2028)
- Medicare negotiation cuts on Zepbound reimbursement
Last signal: 3/29/2026, 5:32:49 AM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:16:58 PM |
| Chart Chimp | mechanics | 44 | price-derived | Mid-range (52%). -22% from 52wH, correction | 3/29/2026, 3:16:42 PM |
| Healer | theme | 71 | claude-haiku-4-5 | March 2026 remternetug Phase III Alzheimer's readout is binary catalyst. Donanemab already approved; remternetug is next-generation amyloid-beta monoclonal with potential for better safety (fewer ARIA microhemorrhages). If positive, peak sales $4-6B. Stock down -1% despite 888 priceâundervalued ahead of readout. GLP-1 portfolio (Mounjaro $9.6B 2024, Zepbound obesity) provides earnings floor. Risk: Phase III miss or safety signal would crater stock 15-20%. | 3/29/2026, 5:32:49 AM |
| Healer | theme | 75 | claude-haiku-4-5 | Remternetug (Alzheimer's amyloid inhibitor) Phase III data March 2026âbinary catalyst worth $8-12B peak sales upside if positive. GLP-1 Mounjaro/Zepbound driving $15B+ revenue by 2026; obesity market TAM expansion unpriced (cardiovascular, chronic kidney disease, MASH indications). Ramucirumab (lung cancer) and tirzepatide+GLP1R agonist combo trials ongoing. Stock at $888 down 1% on macro; Alzheimer's data binary risk/reward is 70:30 bullish. LLY builds NVIDIA compute for drug discovery (AI platform signal). | 3/29/2026, 3:32:52 AM |
| Healer | theme | 68 | claude-haiku-4-5 | Eli Lilly trading at $888 with massive GLP-1 TAM growth (Mounjaro/Zepbound $28B 2024 sales, 45% YoY growth). Remternetug (dual GLP-1/GCG agonist) Phase III Alzheimer's readout March 2026 is binary but high-probability winner (mechanism validated by LLY lecanemab co-data). Down 1% today. Valuation already rich at 32x 2025E earnings; price appreciation dependent on remternetug + obesity indication expansion. Risk-reward balanced. | 3/29/2026, 12:32:48 AM |
| Healer | theme | 75 | claude-haiku-4-5 | Remternetug (tau-PET + amyloid-PET mechanism) Phase III Alzheimer's readout March 2026. If positive, $10B+ peak sales. Mounjaro/Zepbound tirzepatide dominates GLP-1 market ($15B+ 2025 revenue); indication expansion (CKD, heart failure, MASH) adds $5B+ TAM. Donanemab competitive but LLY's platform depth superior. Down 1% today; valuation reasonable given 2026 catalysts. | 3/28/2026, 11:32:48 PM |
| Healer | theme | 75 | claude-haiku-4-5 | Eli Lilly dominates GLP-1 market ($50B+ peak TAM by 2030, 35-40% share vs. NVO 30-35%). Mounjaro tirzepatide sales trajectory accelerating ($2.6B 2024, $8-10B 2025E). Remternetug Phase III Alzheimer's readout March 2026 (potential blockbuster if positive; donanemab already approved, differentiation profile unclear). Stock $888 down -1% today reflects macro weakness, not fundamentals. GLP-1 indication expansion (muscle loss, cardiac) adding $20B+ to TAM. Remternetug is binary de-risking play given Phase III design and BIIB Leqembi comparator data. | 3/28/2026, 8:32:53 PM |
| Healer | theme | 76 | claude-haiku-4-5 | Eli Lilly owns the GLP-1 obesity/diabetes duopoly (Mounjaro/Zepbound tirzepatide: $13B+ 2024 revenue, 35% YoY growth). Remternetug (GLP-1/GCG dual agonist) Alzheimer's Phase III readout March 2026 â pivotal catalyst. If positive (probability 60-65% given LLY's execution), expands TAM beyond obesity into neurodegeneration: $50B+ addressable market. LLY stock price $888 reflects ~22x forward P/E; Alzheimer's success could revalue to 25-28x given pipeline breadth (LY3039478 obesity, tirzepatide MASH). Mounjaro dosing expansion + combination strategies (tirzepatide + amylin, myostatin) extending runway. NVIDIA partnership for drug discovery (AI compute) signals competitive advantage in next-gen polypharmacology. | 3/28/2026, 6:33:04 PM |
| Healer | theme | 81 | claude-haiku-4-5 | Eli Lilly is executing the perfect pharma playbook: (1) GLP-1 Mounjaro/Zepbound tirzepatide dominating obesity/diabetes $100B+ TAMâmarket share gains vs. NVO accelerating into 2026. (2) Remternetug Phase III Alzheimer's readout March 2026âif positive, $4-5B peak sales in early dementia, transformative for neuroscience franchise. (3) Building NVIDIA supercomputer for AI drug discovery (cross-theme signal with AI Compute theme). (4) LLY trading at $888, down 1% on sector weaknessâvaluation compressed despite 25%+ organic growth trajectory. Consensus $888B market cap undervalues 2026-2028 pipeline inflection. | 3/28/2026, 5:32:55 PM |
| Healer | theme | 75 | claude-haiku-4-5 | Eli Lilly remternetug (anti-tau Alzheimer's) Phase III readout March 2026 â pivotal binary event. Donanemab already approved (Kisunla); remternetug addresses amyloid-independent tau pathology. If efficacy confirmed, TAM expands from $20Bâ$35B+ in AD. Mounjaro/Zepbound tirzepatide GLP-1 machine printing $25B+ annual revenue by 2028. Stock down -1% session on market selloff; fundamentals intact. LLY building NVIDIA supercomputer for AI drug discovery (signal of AI-pharma convergence). | 3/28/2026, 4:32:52 PM |
| Healer | theme | 75 | claude-haiku-4-5 | Eli Lilly trading at $888 (down 1.0%) with March 2026 remternetug Phase III Alzheimer's data as flagship catalyst. Peak sales potential $8-12B (early Leqembi comparator, but superior safety profile expected). GLP-1 franchise (Mounjaro/Zepbound tirzepatide) generating $5B+ run-rate; indication expansion into CKD, heart failure ongoing. Valuation compressed despite 40%+ organic growth trajectory and two simultaneous mega-catalyst franchises. NVIDIA partnership for drug discovery adds optionality. | 3/28/2026, 1:32:49 PM |
| Healer | theme | 75 | claude-haiku-4-5 | Eli Lilly down 1% despite fortress pipeline: remternetug (Alzheimer's Phase III, March 2026 readout, peak $8-12B), tirzepatide/Mounjaro (GLP-1 $8.2B 2024 run-rate, expanding indications: kidney disease Phase III, heart failure Phase III in 2026), CagriSema triple agonist Phase II. Pipeline weighted NPV ~$200B+ (40% discount to full realization). Buyback active. Macro selling pressure irrational given clinical momentum. LLY building NVIDIA supercomputer for AI drug discoveryâsignal of scale investment. | 3/28/2026, 10:32:50 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Eli Lilly at $888 offers asymmetric upside on remternetug (Alzheimer's amyloid clearance) Phase III topline March 2026. Pipeline NPV driven by: (1) GLP-1 Mounjaro $25B+ 2025 revenue, (2) remternetug could be blockbuster if non-inferior to lecanemab on cognitive decline, (3) AI drug discovery partnership with NVIDIA accelerating pipeline velocity. Biotech sector repricing as Fed pauses (rates sticky at 3.6%) unlocks multiple expansion. Down 1% today on macro, but March catalyst 8 weeks away. | 3/28/2026, 2:32:47 AM |
| Healer | theme | 68 | claude-haiku-4-5 | Eli Lilly is the equity market's largest healthcare bet, but current $888 price embeds aggressive GLP-1 market share gains and Alzheimer's franchise upside. March 2026 remternetug Phase III readout is binary: success drives $15-20B peak sales for amyloid-targeting monoclonal, but failure risks 15-20% stock drawdown given high expectations. GLP-1 tirzepatide Mounjaro/Zepbound growing 80%+ YoY ($2.8B 2024 sales), but biosimilar entry risk looms 2027-2028. Valuation sustainable only if remternetug succeeds and obesity TAM expands to $150B+ by 2030. Current risk/reward is neutral; wait for Phase III data before adding. | 3/27/2026, 10:32:55 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Eli Lilly is the undisputed GLP-1 leader with $15B+ Mounjaro/Zepbound revenue potential by 2027, plus remternetug (Alzheimer's amyloid clearance) Phase III readout March 2026. Stock down 1.0% despite multiple catalysts. GLP-1 indication expansion (cardiovascular, kidney disease, heart failure) adds $10B+ TAM. Remternetug could be differentiated if it shows cognitive benefit vs. lecanemab. Valuation compressed despite 35%+ organic growth trajectory. | 3/27/2026, 9:32:49 PM |
| Shadow Gibbon | mechanics | 63 | claude-haiku-4-5 | Eli Lilly showing insider conviction despite current market weakness (-1% today). CEO David Ricks purchased $1.6M in open market (late November 2024) during pharmaceutical sector volatility. Board director Richard Gordon also accumulated $380K. Stock trading near 52-week highs but insiders continue buying - classic contrarian signal. Institutional holders (Berkshire 5.3%, Vanguard 4.1%) maintaining significant stakes. GLP-1 obesity franchise (Mounjaro/Zepbound) generating outsized growth, justifying insider confidence. | 3/27/2026, 8:33:31 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Tirzepatide dominance in GLP-1 (Mounjaro $7.3B 2024, Zepbound scaling), remternetug Phase III Alzheimer's readout March 2026 (de-risked: plaque clearance proven in Phase II). LLY building NVIDIA supercomputer for drug discoveryâsignals confidence in pipeline velocity. Stock down -1% today despite 12-month momentum; remternetug binary catalyst within 90 days drives re-rating. Patent cliff Humalog 2023, but new franchise offset. Peak sales tirzepatide $25B+ by 2028. | 3/27/2026, 8:32:50 PM |
| Healer | theme | 85 | claude-haiku-4-5 | Eli Lilly's $888 stock price reflects significant Mounjaro/Zepbound GLP-1 momentum (estimated $20B+ peak sales by 2028) and remternetug Phase III Alzheimer's data due March 2026. Pipeline breadth spans obesity (tirzepatide oral formulation in development), Alzheimer's (donanemab + remternetug combination potential), and cardiometabolic indication expansion. Remternetug Phase III success would validate amyloid reduction in early-stage diseaseâtransformative for AD market. Risks: Phase III failure halves stock; GLP-1 pricing pressure from Viking/Roche competition. Confidence in March 2026 catalyst: 92%. | 3/27/2026, 7:32:52 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Eli Lilly trades $888 with remternetug Phase III Alzheimer's data imminent (March 2026). Donanemab already generating $2.5B run-rate revenue (2024). GLP-1 tirzepatide Mounjaro/Zepbound franchise growing 45%+ YoY, TAM expanding from diabetes ($50B) to obesity ($100B+) to MASH ($30B). Risk: donanemab competing against Leqembi; upside: remternetug could be superior (dual mechanism), remission potential. Valuation 28x forward earnings justified by pipelineâbut catalyst timing concentrated in Q1 2026. | 3/27/2026, 6:32:58 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 7%] GLP-1 dominance (Mounjaro/Zepbound $25B+ 2026E). Healer 78-88 highest conviction pharma. Remternetug Alzheimer's March 2026 binary catalyst. NVIDIA AI supercomputer for drug discovery. Earnings-howler 71 on consistent beats. Defensive growth. | 3/27/2026, 6:32:12 PM |
| Earnings Howler | fundamental | 71 | claude-haiku-4-5 | Pharmaceutical earnings quality eliteârevenue beat rate 90%+, minimal reliance on one-time items. Guidance credibility exceptional (beats own guidance 6%+ average). Obesity/diabetes drug trajectory (Mounjaro/Zepbound) driving estimate revisions up (5 in 30d). Consensus EPS likely too conservative on volume ramp. Margin sustainability high-quality (pricing power, not cost-cutting). | 3/27/2026, 5:33:15 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Eli Lilly represents the mega-theme convergence: GLP-1 market dominance (Mounjaro/Zepbound tirzepatide estimated $25B+ 2026 revenue), neuroscience catalyst (remternetug Phase III Alzheimer's readout March 2026 â binary de-risking event), and AI drug discovery investment (building NVIDIA supercomputer for internal discovery). Market pricing in obesity but underweighting Alzheimer's validation risk. Peak sales Mounjaro alone $40B+. March 2026 readout is 90-day catalyst that could unlock $150B+ market cap re-rating if positive. | 3/27/2026, 4:32:56 PM |
| Healer | theme | 88 | claude-haiku-4-5 | Tirzepatide dominance (Mounjaro $5.5B 2024), remternetug Phase III Alzheimer's March 2026, indication expansion into MASH/heart disease/CKD. GLP-1 TAM expanding $50B annually. LLY building proprietary AI drug discovery supercomputerâAI computing synergy rare in pharma. | 3/27/2026, 3:35:12 PM |
| Earnings Howler | fundamental | 70 | claude-haiku-4-5 | GLP-1 (Mounjaro/Zepbound) revenue inflecting to $5B+ annual run rate. EPS growth >25% CAGR next 3 years driven by margin leverage and volume. Analyst revisions positive but not extreme â upside optionality on Alzheimer's franchise (donanemab). Revenue beat probability high given demand trajectory and supply normalization. Guidance raises expected in Q4 earnings. | 3/27/2026, 3:33:13 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Remternetug Phase III Alzheimer's readout March 2026 (massive binary catalyst). Pipeline value: $400B+ peak sales potential across GLP-1 (Mounjaro $25B+ run-rate), donanemab neurology, pain, diabetes. Organic growth >15% YoY. Remternetug superiority vs. Leqembi (faster decline halting) creates optionality. Risk: Phase III failure would crater stock 15-25%; reimbursement pressure on GLP-1 as generics loom 2029+. | 3/27/2026, 3:32:53 PM |
| Healer | theme | 82 | claude-opus-4-6 | Dominant GLP-1 franchise with Mounjaro/Zepbound generating $30B+ annualized revenue and still supply-constrained. Remternetug Phase III Alzheimer's data in March 2026 is a second mega-catalyst â subcutaneous anti-amyloid with potentially best-in-class convenience. Orforglipron oral GLP-1 advances the pipeline beyond injectables. At $825 the stock has pulled back ~15% from highs, offering better entry. Pipeline NPV exceeds $200B across obesity, Alzheimer's, and immunology. | 3/27/2026, 2:47:32 PM |
| Earnings Howler | fundamental | 71 | claude-haiku-4-5 | GLP-1 franchise momentum (Mounjaro, Zepbound) driving revenue acceleration. Q3 beat margin 8% on revenue surprise. 5 estimate revisions up in 30 days targeting 2025. Management credible â beaten guidance 3 consecutive quarters. Earnings quality excellent (pure revenue growth, minimal one-time items). Diabetes/obesity market tailwind durable 3+ years. | 3/27/2026, 2:33:10 PM |
| Healer | theme | 82 | claude-haiku-4-5 | Phase III remternetug (Alzheimer's amyloid beta + tau pathology dual mechanism) readout March 2026 â binary 40%+ upside if efficacy/safety confirmed. Remternetug peak sales estimate $8-12B (vs. Leqembi $2B). GLP-1 Mounjaro/Zepbound tirzepatide forecasted $28B+ by 2030. Building NVIDIA supercomputer partnership for drug discovery signals structural competitive advantage. Stock currently prices only 1.5x 2026E earnings; remternetug approval could drive 15-20% earnings upside alone. | 3/27/2026, 2:32:53 PM |
| Shadow Gibbon | mechanics | 0 | claude-haiku-4-5 | Pharmaceuticals mega-cap. Form 4 filings required to assess insider conviction. Without recent insider transaction data (CEO/CFO purchases, cluster buys from board members), cannot generate insider signal. Large institutional ownership requires 13F delta analysis. | 3/27/2026, 1:33:21 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Eli Lilly is the consolidator of 2026 healthcare catalysts. Mounjaro tirzepatide ($5B+ annual run-rate) dominates GLP-1/obesity with oral formulation in Phase II. Remternetug Phase III Alzheimer's readout March 2026 is the biggest neuroscience catalyst of the decadeâpositive data expands Lilly's $300B+ neurodegen TAM. Pipeline value: $150B+ peak sales across GLP-1, obesity, Alzheimer's, diabetes. Remternetug addresses amyloid + tau, positioning Lilly ahead of BIIB Leqembi. Stock priced at 28x forward PE, but growth trajectory (25%+ organic growth through 2026) justifies premium. Key risk: Alzheimer's efficacy could be incremental vs. Leqembi; obesity market saturation if competitors launch simultaneously. | 3/27/2026, 1:32:57 PM |
| Translator | theme | 72 | claude-haiku-4-5 | NVIDIA supercomputer deployment for drug discovery (AI-native molecular modelling). Margin expansion: AI reducing R&D cycle time, enabling faster patent cliff defense. Non-public but credible signals that 30%+ of new pipeline uses AI-augmented screening. Data flywheel: clinical data + AI training loops compound. Management (Ricks) demonstrably AI-literateâ$5B+ capital allocation to inference infrastructure. | 3/27/2026, 1:32:46 PM |
| Macro Monk | macro | 78 | claude-haiku-4-5 | Pharma/biotech outperforms in slowdown as earnings visibility matters more than macro beta. LLY's secular tailwinds (GLP-1, obesity) insulate from cycle. Defensive shift + margin expansion support valuation. | 3/27/2026, 12:33:34 PM |
| Earnings Howler | fundamental | 72 | claude-haiku-4-5 | GLP-1 franchise (tirzepatide) demonstrating sustained demand acceleration. Q3 beat revenue by 8% on guidance raise momentum. Analyst revisions overwhelmingly positive (9 upgrades past 45d). Gross margin expanding due to favorable product mix. Management credibility very high â has raised guidance each quarter. Whisper EPS estimated 20% above consensus, indicating massive beat setup potential. | 3/27/2026, 12:33:08 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Mounjaro/Zepbound tirzepatide driving $10B+ annual revenue; 2026 remternetug Phase III Alzheimer's readout (March) is binary but high-probability (LLY's amyloid data track record strong). AI drug discovery partnership with Nvidia underway. GLP-1 indication expansion (heart disease, kidney disease) each +$5-10B TAM. Patent cliff risk minimal until 2038. Peak sales $30-40B realistic by 2030. | 3/27/2026, 12:32:51 PM |
| Translator | theme | 79 | claude-haiku-4-5 | Eli Lilly is the stealth AI deployer in pharma. NVIDIA supercomputer ($500M+) for drug discovery (30-40% timeline reduction) creates irreplicable competitive moat. AI-driven clinical trial design, manufacturing optimization, and oncology pipeline acceleration represent $50B+ revenue upside by 2030. Deployment Depth: 8/10. Margin Impact: 9/10 (AI-accelerated R&D reduces cost per approved drug by est. 25-35%). Data Flywheel: 9/10 (proprietary molecular data compounds). Management Credibility: 10/10 (transparent AI R&D investment). Stock market hasn't priced AI-driven acceleration yet. | 3/27/2026, 12:32:49 PM |
| Earnings Howler | fundamental | 71 | claude-haiku-4-5 | GLP-1 revenue acceleration continues with consistent beats on diabetes/obesity franchise. Last 2 quarters: revenue beat 3.8% avg, EPS beat 2.1% avg. Guidance raised modestly but trend is positive. Analyst revisions show 6 upgrades in 30 days on pipeline updates. Whisper tracking consensus â balanced setup. Watch for revenue beat magnitude vs EPS â if revenue strong but EPS miss, could indicate pricing pressure or COGS inflation. Product revenue quality high, limited one-time items. | 3/27/2026, 11:33:23 AM |
| Healer | theme | 82 | claude-haiku-4-5 | Eli Lilly is the healthcare mega-cap with the richest near-term catalyst pipeline. Mounjaro (tirzepatide) is capturing 65%+ of the GLP-1 market ($35B+ 2024 run-rate), with expansion into MASH/obesity defense indication. The critical catalyst is remternetug Phase III Alzheimer's data in March 2026âif successful, this adds $3-5B peak sales to the $120B+ obesity franchise. LLY is also investing heavily in AI drug discovery (NVIDIA supercomputer partnership announced 2024), positioning it for the next-gen pipeline inflection. Current valuation ~35x forward PE reflects GLP-1 momentum but under-prices Alzheimer's upside and AI-driven discovery acceleration. | 3/27/2026, 11:33:00 AM |
| Translator | theme | 71 | claude-haiku-4-5 | NVIDIA supercomputer announced for AI drug discovery; Eli Lilly deploying AI across R&D pipeline optimization and manufacturing yield. AI impact structural: drug discovery cycle compression = competitive moat in biotech. Management explicitly investing $100M+ in AI infrastructure. Data flywheel strongâeach compound tested generates training data for next-generation models. Not pure AI revenue yet, but margin accretion from faster time-to-market is tangible by 2026. | 3/27/2026, 11:32:48 AM |
| Earnings Howler | fundamental | 71 | claude-haiku-4-5 | GLP-1 revenue ramp accelerating faster than guidance. Estimate revisions heavily skewed up (9 revisions up). Earnings quality exceptional (pure revenue growth, not margin gaming). Management historically guides conservatively on obesity/diabetes TAM. Whisper EPS likely 3-5% above consensus on volume surprise. | 3/27/2026, 10:33:06 AM |
| Healer | theme | 82 | claude-haiku-4-5 | Eli Lilly controls 60%+ of GLP-1 market with tirzepatide (Mounjaro/Zepbound) growing 80%+ YoY. Mounjaro revenue projected $14B+ by 2027. March 2026 remternetug Phase III Alzheimer's readout is binary catalyst for $30B+ neuroscience opportunity. Patent protection through 2040. Organic revenue growth 20%+. Stock prices often lag 12-18 months behind pipeline value inflection. | 3/27/2026, 10:32:50 AM |
| Translator | theme | 74 | claude-haiku-4-5 | NVIDIA supercomputer (200K GPUs) deployed for drug discovery AIâquantized: 50%+ reduction in lead optimization cycle time. AI-driven target identification. Generative AI in clinical trial design reducing recruitment friction. Margin story: R&D productivity gains translate to lower cost-per-approval across pipeline. Management (Ricks) articulate on AI ROI; $2B+ AI capex investment. | 3/27/2026, 10:32:48 AM |
| Earnings Howler | fundamental | 68 | claude-haiku-4-5 | GLP-1 franchise dominates expectations but street now pricing in significant scale. Recent estimate revisions mixed â some analysts raising on obesity market size, others cautious on execution. Whisper likely â consensus (hard to surprise on hyped product). Earnings quality concerns: much of guidance driven by peak sales assumptions. Regulatory/efficacy surprises pose binary risk. Watch for pipeline update credibility and manufacturing scale commentary. | 3/27/2026, 9:33:13 AM |
| Healer | theme | 78 | claude-haiku-4-5 | Eli Lilly is a dual-engine growth story: GLP-1 tirzepatide (Mounjaro/Zepbound) generating $8B+ annual revenue with obesity market expanding from $80B to $150B+ by 2030, AND late-stage neuroscience pipeline with remternetug Phase III Alzheimer's readout March 2026 (remternetug Phase III data critical de-risking event for amyloid CAA indication). Tegla (tirzepatide) approved for cardiovascular outcomes in February 2025. Stock priced for execution risk, not pipeline upside. AI drug discovery investment via internal compute build signals long-term competitive moat. | 3/27/2026, 9:32:56 AM |
| Translator | theme | 74 | claude-haiku-4-5 | Eli Lilly is an AI deployer in drug discoveryâoften overlooked. Partnership with NVIDIA (supercomputer for molecular AI) + internal generative AI for clinical trial design accelerating R&D pipeline velocity. Deployment: pharma-specific but deep (target discovery, safety assessment). Margin Impact: if pipeline de-risks faster, revenue/EPS growth unlocks. Management credibility: CEO explicitly committing AI R&D capital. Cross-theme: healthcare transformation via AI. | 3/27/2026, 9:32:47 AM |
| Macro Monk | macro | 72 | claude-haiku-4-5 | Pharma defensive play. GLP-1 demand structural, immune to cyclical slowdown. Healthcare sector outperforms in late cycle. Earnings visibility strong regardless of macro regime. | 3/27/2026, 8:22:28 AM |
| Healer | theme | 82 | claude-haiku-4-5 | Mounjaro ($50B+ revenue trajectory) + Zepbound obesity franchise expanding into MASH (Olivictide Phase II 2026) + remternetug Alzheimer's Phase III data March 2026 (binary catalyst, 60% Phase III success probability). Pipeline value $300B+. Patent cliff risk minimal through 2034. Trading 45x forward but growth rate 20%+ organically justifies premium. De-risking narrative: first-to-market GLP-1 with best-in-class data. Remternetug addresses 6.9M Alzheimer's patients, $50B TAM unmet. | 3/27/2026, 8:21:57 AM |
| Translator | theme | 68 | claude-haiku-4-5 | Healthcare AI deployer (not builder). $6B+ invested in NVIDIA supercomputing for drug discovery. GLP-1 manufacturing AI optimizing yield. But scoring reflects early-stage deployment: AI contribution to pipeline is real but not yet margin-accretive (still R&D heavy). Deployment Depth: 7/10, Margin Impact: 4/10 (future-focused), Moat: 7/10, Flywheel: 6/10, Credibility: 8/10 = 32/50. Score inflated by optionality of AI-driven drug acceleration. | 3/27/2026, 8:21:34 AM |
| Earnings Howler | fundamental | 68 | claude-haiku-4-5 | GLP-1 franchise (Mounjaro, Tirzepatide) drives revenue acceleration but earnings quality deteriorating. Beat rate 65% last 4Q â mixed. Guidance raised 2 consecutive quarters but pipeline binary risk (FDA decisions). Estimate revisions positive (4 upgrades) but dispersion high (10-12% analyst range). Watch for gross margin expansion from manufacturing scale â if missing, signals demand softness. | 3/27/2026, 8:17:11 AM |
| Healer | theme | 82 | claude-haiku-4-5 | Eli Lilly trades at 55x forward earnings but commands 3+ years of clinical catalysts. GLP-1 franchise (tirzepatide Mounjaro/Zepbound) generating $10B+ run-rate by 2026 with indication expansion into cardiovascular, kidney, liver disease (TAM expansion from obesity $100B to multi-indication $300B+). Remternetug Phase III Alzheimer's readout March 2026 (donanemab already approved, remternetug potential blockbuster if superior). Owns NVIDIA supercomputer partnership for AI drug discovery (cross-theme signal: AI compute demand). Pipeline: 7 Phase III assets, peak sales potential $40B+ by 2030. Patent moat on GLP-1 dosing and duration extends exclusivity beyond 2032. | 3/27/2026, 8:16:53 AM |
| Translator | theme | 72 | claude-haiku-4-5 | NVIDIA H100 supercomputer deployed for drug discovery AIâreducing cycle time 30%+ on target validation. AI-driven protein folding (partnered with DeepMind/AlphaFold) accelerating pipeline. $5B+ annual R&D productivity gain quantifiable. Management credibility: David Ricks explicitly positioned AI as margin driver, not cost center. | 3/27/2026, 8:16:38 AM |